In summary, our results strongly support the hypothesis that drug treatment regimens that lead to enhanced mda-7/IL-24 expression in cancer cells and block NF-κB may have significant efficacy against ovarian cancer. The gene discussed is NFKB1; the disease is ovarian cancer.